Pharmaceutical company Astellas Pharma Inc. (TSE:4503) announced on Friday that the US FDA has approved VYLOY (zolbetuximab-clzb) in combination with chemotherapy for first-line treatment of adults with CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
VYLOY is the first CLDN18.2-targeted therapy approved in the US, based on Phase 3 SPOTLIGHT and GLOW trials that demonstrated improved progression-free and overall survival compared to chemotherapy alone.
Astellas collaborated with Roche to develop the VENTANA CLDN18 (43-14A) RxDx Assay, an FDA-approved diagnostic test to identify eligible patients. VYLOY is now approved in five global markets, including Japan, the UK, the EU, South Korea and the US Additional regulatory reviews are ongoing worldwide.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA